Latest News and Updates | Cantargia

* (R) = Regulatory press releases

Jun 10, 2016

(R) Cantargia receives Notice of Allowance from USPTO on IL1RAP in solid tumours

Jun 8, 2016

(R) Cantargia receives patent approval in Japan for solid tumours

Jun 8, 2016

(R) Cantargia receives Notice of Allowance from USPTO on IL1RAP in acute lymphatic leukemia

May 16, 2016

(R) Cantargia interim report January – March 2016

Apr 20, 2016

(R) Cantargia raises SEK 31.4 million through exercise of warrants of series TO 1 and TO 3

Mar 21, 2016

(R) Cantargia receives patent approval in Japan and Mexico

Mar 10, 2016

(R) Cantargia secures exercise of warrants of series TO 1

Mar 9, 2016

(R) Cantargia AB’s CAN04 product candidate shows good safety after repeated doses in new toxicity study

Mar 1, 2016

(R) Cantargia Year-end report January – December 2015

Feb 3, 2016

(R) Cantargia patent granted in Australia

<< Newer press releases Older press releases >>

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye